Taysha Gene Therapies Inc Ordinary Shares TSHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
-
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12
-
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Taysha Gene Therapies to End Development of TSHA-120 After FDA Feedback
-
Taysha Gets FDA Fast-Track for Rett Syndrome Treatment
Trading Information
- Previous Close Price
- $2.10
- Day Range
- $2.09–2.15
- 52-Week Range
- $1.27–4.32
- Bid/Ask
- $2.13 / $2.14
- Market Cap
- $437.55 Mil
- Volume/Avg
- 234,920 / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 53.86
- Price/Sales
- 32.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- https://www.tayshagtx.com
Comparables
Valuation
|
Metric
|
TSHA
|
TVTX
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | 53.86 | — | — |
Price/Book Value | 3.88 | 75.92 | 1.72 |
Price/Sales | 32.67 | 6.51 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
TSHA
TVTX
PLRX
Financial Strength
|
Metric
|
TSHA
|
TVTX
|
PLRX
|
|---|---|---|---|
Quick Ratio | 5.05 | 2.89 | 14.21 |
Current Ratio | 5.22 | 3.04 | 14.47 |
Interest Coverage | −52.79 | −35.20 | −106.49 |
Quick Ratio
TSHA
TVTX
PLRX
Profitability
|
Metric
|
TSHA
|
TVTX
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −40.83% | −9.03% | −27.65% |
Return on Equity (Normalized) | −216.63% | −47.00% | −31.11% |
Return on Invested Capital (Normalized) | −77.31% | −13.68% | −33.69% |
Return on Assets
TSHA
TVTX
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nrsvthkbc | Sxvn | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ccrndcztj | Fwpzbkg | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nkqntyjq | Nvcxqqk | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mzmjsbvkr | Qgpslg | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Pjzhmgfk | Snbv | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Twydccyb | Mxw | $28.0 Bil | |||
| Moderna Inc
MRNA
| Wsrjqkdrd | Zygx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Wfqzxkfz | Xdszq | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tprtrqpx | Rqpyh | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Dwcxlgtwmm | Rfnrqqg | $12.6 Bil |
United States